| Tag | Content |
|---|---|
| UniProt Accession | RXRA_HUMAN; P19793; |
| Entrez ID | 6256 |
| GenBank Protein ID | NM_001291921.1; NM_002957.5; |
| GenBank Nucleotide ID | NP_001278850.1; NP_002948.1; |
| Protein Name | Retinoic acid receptor RXR-alpha (Nuclear receptor subfamily 2 group B member 1) (Retinoid X receptor alpha) |
| Gene Name | RXRA; NR2B1 |
| Organism | Homo sapiens |
| NCBI Taxa ID | 9606 |
| Functional Description | Receptor for retinoic acid. Retinoic acid receptors bind as heterodimers to their target response elements in response to their ligands, all-trans or 9-cis retinoic acid, and regulate gene expression in various biological processes. The RAR/RXR heterodimers bind to the retinoic acid response elements (RARE) composed of tandem 5'-AGGTCA-3' sites known as DR1-DR5. The high affinity ligand for RXRs is 9-cis retinoic acid. RXRA serves as a common heterodimeric partner for a number of nuclear receptors. In the absence of ligand, the RXR-RAR heterodimers associate with a multiprotein complex containing transcription corepressors that induce histone acetylation, chromatin condensation and transcriptional suppression. On ligand binding, the corepressors dissociate from the receptors and associate with the coactivators leading to transcriptional activation. The RXRA/PPARA heterodimer is required for PPARA transcriptional activity on fatty acid oxidation genes such as ACOX1 and the P450 system genes. |
| Sequence (Fasta) | MDTKHFLPLD FSTQVNSSLT SPTGRGSMAA PSLHPSLGPG IGSPGQLHSP ISTLSSPING 60 MGPPFSVISS PMGPHSMSVP TTPTLGFSTG SPQLSSPMNP VSSSEDIKPP LGLNGVLKVP 120 AHPSGNMASF TKHICAICGD RSSGKHYGVY SCEGCKGFFK RTVRKDLTYT CRDNKDCLID 180 KRQRNRCQYC RYQKCLAMGM KREAVQEERQ RGKDRNENEV ESTSSANEDM PVERILEAEL 240 AVEPKTETYV EANMGLNPSS PNDPVTNICQ AADKQLFTLV EWAKRIPHFS ELPLDDQVIL 300 LRAGWNELLI ASFSHRSIAV KDGILLATGL HVHRNSAHSA GVGAIFDRVL TELVSKMRDM 360 QMDKTELGCL RAIVLFNPDS KGLSNPAEVE ALREKVYASL EAYCKHKYPE QPGRFAKLLL 420 RLPALRSIGL KCLEHLFFFK LIGDTPIDTF LMEMLEAPHQ MT 463 |
|
||||||||||||||||||||
| Database | Annotation |
|---|---|
| CTD (Curated) (count: 5) | MESH:C531617
; Amyotrophic lateral sclerosis 1 MESH:C562839 ; Mesothelioma, Malignant MESH:D011471 ; Prostatic Neoplasms MESH:D020426 ; Sciatic Neuropathy MESH:D013964 ; Thyroid Neoplasms |
| GWASdb (count: 17) (view all) | rs4917350; Urinary metabolites; kidney disease
rs4917352; Urinary metabolites; kidney disease rs12351482; Smoking initiation; nicotine dependence rs34312136; Intelligence; attention deficit hyperactivity disorder|cognitive disorder rs34090729; Cholesterol, total; coronary artery disease|lipid metabolism disorder|arteriosclerosis rs34090729; Triglycerides; coronary artery disease|lipid metabolism disorder|arteriosclerosis |
| PTM | Modification Sites |
|---|---|
| Phosphorylation (count: 20) (view all) | 12 HFLPLDFSTQVNSSL dbPAF
129 HPSGNMASFTKHICA dbPAF 147 DRSSGKHYGVYSCEG dbPAF 150 SGKHYGVYSCEGCKG dbPAF 17 DFSTQVNSSLTSPTG dbPAF 20 TQVNSSLTSPTGRGS dbPAF |
| Acetylation (count: 2) | 145 CGDRSSGKHYGVYSC PLMD
417 EQPGRFAKLLLRLPA PLMD |
| Ubiquitination (count: 3) | 356 VLTELVSKMRDMQMD PLMD
364 MRDMQMDKTELGCLR PLMD 417 EQPGRFAKLLLRLPA PLMD |
| Sumoylation (count: 1) | 108 VSSSEDIKPPLGLNG PLMD |
| Network | Interaction | ||
|---|---|---|---|
| A | B | Source | |